Semaglutide therapy is contraindicated for individuals with medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and those who are pregnant due to potential adverse fetal outcomes
While some have hailed it as a miracle injection, others have endured significant physical and emotional harm
Current batch RE7392 99.82% Tested March 2026 View Certificate of Analysis Batch RE7392 Customer Reviews No reviews yet Be the first to review this product
doi:10.1002/ptr.6349
(Its worth noting that the committee was heavily made up of pro-peptide individuals, including doctors, and its also worth noting that the FDA itself advised against loosening restrictions, saying theres just not enough clinical evidence yet.) Approved peptides are thus eligible to be moved to the Section 503A Bulk List, which means compounding pharmacies could legally prepare said peptides for patientswith a valid prescription and specific quality and testing standards
(3) Other Not-Always-Prohibited Substances/ markers of high risk contaminations: Other substances of conditional or contextual anti-doping relevance, included to reflect documented cases of multi-substance contamination where non-prohibited compounds are analytically detected alongside prohibited substances and may contribute to regulatory ambiguity or unintentional doping risk